Results of interferon-alfa therapy in patients with Behcet uveitis

被引:111
|
作者
Tugal-Tutkun, Ilknur [1 ]
Guney-Tefekli, Esra [1 ]
Urgancioglu, Meri [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Ophthalmol, Istanbul, Turkey
关键词
Behcet disease; interferon-alpha; 2a; uveitis;
D O I
10.1007/s00417-006-0346-y
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report on the results of interferon-alpha 2a (IFN alpha) treatment in patients with Behcet uveitis unresponsive to conventional immunosuppressive therapy. Methods: We retrospectively analyzed the medical records of 44 patients who had been treated with IFN alpha between September 2001 and May 2005. The initial dose of IFN alpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity. Results: Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4 +/- 10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2 +/- 13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6 +/- 1.2 to 0.8 +/- 0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFN alpha therapy (p < 0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients. Conclusions: A partial or complete response was obtained with IFN alpha therapy in 91% of Turkish patients with Behcet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFN alpha in different patient populations. Comparative studies are needed to investigate this hypothesis.
引用
收藏
页码:1692 / 1695
页数:4
相关论文
共 50 条
  • [41] Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients
    Hayashida, K
    Daiba, A
    Sakai, A
    Tanaka, T
    Kaji, K
    Inaba, N
    Ando, S
    Kajiyama, N
    Terasaki, H
    Abe, A
    Ogasawara, M
    Kohara, M
    Harada, M
    Okanoue, T
    Ito, S
    Kaneko, S
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (12) : 1253 - 1259
  • [42] RESPONSE OF DEEP TUFTED ANGIOMA TO INTERFERON-ALFA
    SUAREZ, SM
    PENSLER, JM
    PALLER, AS
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1995, 33 (01) : 124 - 126
  • [43] Role of interferon-alfa in NHL: Still controversial?
    Haase-Statz, S
    Smalley, RV
    ONCOLOGY-NEW YORK, 1999, 13 (08): : 1147 - +
  • [44] Pharmacokinetic-pharmacodynamic relationships of merimepodib and ribavirin in pegylated interferon-alfa/ribavirin/merimepodib treated genotype-1 HCV patients non-responsive to previous therapy with interferon-alfa/ribavirin
    Zha, JH
    Garg, V
    McNair, L
    Marcellin, P
    Alam, J
    Purdy, S
    Ette, E
    HEPATOLOGY, 2004, 40 (04) : 250A - 250A
  • [45] Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behcet's Disease
    Park, Ji-Youn
    Chung, Yoo-Ri
    Lee, Kihwang
    Song, Ji Hun
    Lee, Eun-So
    YONSEI MEDICAL JOURNAL, 2015, 56 (04) : 1158 - 1162
  • [46] Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease
    Wechsler, B
    Bodaghi, B
    Huong, DLT
    Fardeau, C
    Amoura, Z
    Cassoux, N
    Piette, JC
    LeHoang, P
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2000, 8 (04) : 293 - 301
  • [47] The multifocal ERG-system in ocular Behcet's disease for monitoring the interferon-alfa 2a treatment
    Stuebiger, N
    Besch, D
    Deuter, CME
    Zierhut, M
    Koetter, I
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U417 - U417
  • [48] Interferon alfa for Behcet's disease?
    不详
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1997, 81 (12) : 1030 - 1030
  • [49] INTERFERON-ALFA THERAPY OF CHRONIC HEPATITIS-C VIRUS-INFECTION IN CHILDREN
    JONAS, MM
    NELSON, SP
    OTT, MJ
    HEPATOLOGY, 1995, 22 (04) : 39 - 39
  • [50] Management of psychiatric adverse events with immunotherapy with interferon-alfa
    Van Gool, AR
    Kruit, WHJ
    Cornelissen, JJ
    Berk, L
    Eggermont, AMM
    Bannink, M
    ACTA NEUROPSYCHIATRICA, 1999, 11 (04): : 120 - 124